Table 1.
Patient demographics.
| Characteristic Age—median (range) | 67.25 (35–83) |
| Gender—no. (%) male female | 16 (40) 24 (60) |
| Stage of disease (AJCC)*—no. (%) | |
| M1a | 14 (35) |
| M1b | 6(15) |
| M1c | 20 (50) |
| Prior systemic therapy—no. (%) | |
| none | 15 (37.5) |
| IL2 | 16 (40) |
| Temozolomide | 8 (20) |
| BRAF inhibitor | 1 (2.5) |
| Series of Ipilimumab—no. (%) | |
| 2 | 3 (7.5) |
| 3 | 2(5) |
| 4 | 35 (87.5) |
| Line of therapy—no. (%) | |
| 1st | 15 (37.5) |
| 2nd | 24 (60) |
| 3rd | 1 (2.5) |
| Lactate dehydrogenase—no. (%) | |
| sULN | 31 (77.5) |
| > ULN | 9 (22.5) |
| >2x ULN | 1 (2.5) |
| RECIST response—no. (%) | |
| PD | 25 (62.5) |
| SD | 9 (22.5) |
| PR | 5 (12.5) |
| CR | 1 (2.5) |